Latest News
Atara Biotherapeutics, Inc.
- Atara Biotherapeutics Inc Estimates – MUN:AT20
- Atara Biotherapeutics Defendants Move to Dismiss Amended Securities Class Action Over Tab-cel FDA Rejection
- Atara Biotherapeutics (ATRA) Edges Up 2.07% to $9.35, Sitting Squarely at the Midpoint of Its Range - Revenue Growth Stocks
- Biotech Movers: Opko Health (NASDAQ:OPK), Atara (NASDAQ:ATRA) Verastem (NASDAQ:VSTM) in Focus
- Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration
- FDA accepts resubmitted application for Atara’s tab-cel therapy By Investing.com
- Atara, Pierre Fabre take third shot at FDA approval of Ebvallo
- Pierre Fabre, Atara resubmit Ebvallo BLA after two FDA CRLs
- Atara, Pierre Fabre resubmit twice-rebuffed cell therapy after FDA flips again
- Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration
Headlines from the last 30 days, linking to the original publishers. See all market news →